Yuhan Corporation’s Lexraza Early Access Program: Strategies for First-Line Treatment Market and Patient Choice
choice for patients? Strategies for occupying the first-line treatment market? CEO Cho Wook-je “There is no purpose to attract patients… Proceed EAP with confidence” Professor of Oncology “Not for companies or hospitals, only for patients” Cho Wook-je, CEO of Yuhan Corporation ⓒUihyup Shinmun Is Yuhan’s free supply of Lexraza a choice for patients? Is it … Read more